The new drug candidate RCI001 currently under development delivers anti-inflammatory effects through the selective modulation of multifunctional signaling molecules.
Moreover, it has shown improvement in tear secretion function, and is currently being developed as an eye drop with the goal of entering clinical trials domestically and internationally next year. RCI001 played a key role in being selected for the 'R&D Rediscovery Project' and other programs.